Notify me when Sands Capital Ventures, LLC files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ABOS | Acumen Pharmaceuticals, Inc. | Common Stock, par value $0.0001 per share | 5.6% | $4.85M | 3.42M | Sands Capital Alternatives, LLC | Jun 30, 2025 | ||
| KVYO | Klaviyo, Inc. | Series A Common Stock, par value $0.001 per share | 4.9% | $128M | 4.42M | SANDS FRANK M. | Mar 31, 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Date Filed |
|---|